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Abstract
Background: To compare the prognostic value of estimated glomerular filtration rate, cystatin-C, an alternative renal
biomarker, and their combination, in an outpatient population with heart failure.Estimated glomerular filtration rate is
routinely used to assess renal function in heart failure patients. We recently demonstrated that the Cockroft-Gault formula is
the best among the most commonly used estimated glomerular filtration rate formulas for predicting heart failure
prognosis.
Methodology/Principal Findings: A total of 879 consecutive patients (72% men, age 70.4 years [P25–75 60.5–77.2]) were
studied. The etiology of heart failure was mainly ischemic heart disease (52.7%). The left ventricular ejection fraction was
34% (P25–75 26–43%). Most patients were New York Heart Association class II (65.8%) or III (25.9%). During a median follow-
up of 3.46 years (P25–75 1.85–5.05), 312 deaths were recorded. In an adjusted model, estimated glomerular filtration rate and
cystatin-C showed similar prognostic value according to the area under the curve (0.763 and 0.765, respectively). In Cox
regression, the multivariable analysis hazard ratios were 0.99 (95% CI: 0.98–1, P= 0.006) and 1.14 (95% CI: 1.02–1.28, P= 0.02)
for estimated glomerular filtration rate and cystatin-C, respectively. Reclassification, assessed by the integration
discrimination improvement and the net reclassification improvement indices, was poorer with cystatin-C (20.5
[21.0;20.1], P= 0.024 and 24.9 [28.8;21.0], P= 0.013, respectively). The value of cystatin-C over estimated glomerular
filtration rate for risk-stratification only emerged in patients with moderate renal dysfunction (eGFR 30–60 ml/min/1.73 m2,
chi-square 12.9, P,0.001).
Conclusions/Significance: Taken together, the results indicate that estimated glomerular filtration rate and cystatin-C have
similar long-term predictive values in a real-life ambulatory heart failure population. Cystatin-C seems to offer improved
prognostication in heart failure patients with moderate renal dysfunction.
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Introduction
Chronic heart failure (HF) is a growing public epidemic with
increasing incidence and prevalence [1]. Despite important
progress in recent decades, mortality remains high among patients
with HF. Renal insufficiency is prevalent among patients with HF,
and the coexistence of both conditions results in a worse prognosis
[2–6]. The most precise methods for calculating kidney function,
including the isotopic glomerular filtration rate and creatinine
clearance in a 24-hour urine specimen, are not utilized in daily
clinical practice [7]. Instead, several formulas based on creatinine
clearance have been developed to determine the estimated
glomerular filtration rate (eGFR), with the Cockroft-Gault formula
[8], the simplified Modification of Diet in Renal Disease (MDRD-
4) equation [9], and the Chronic Kidney Disease Epidemiology
Collaboration equation [10] being the most commonly used in
clinical practice. We recently demonstrated that the Cockroft-
Gault formula is the best among these three eGFR formulas for
predicting long-term prognosis in HF patients [11].
In the last few years, cystatin-C has emerged as a novel renal
biomarker with prognostic implications in patients with HF [12–
13]. However, to the best of our knowledge, no data have assessed
the benefits of cystatin-C over eGFR in terms of prognosis in
patients with chronic HF. The objective of the present study was to
compare the long-term prognostic value of cystatin-C and eGFR
using the Cockroft-Gault formula in an outpatient population with
HF and to assess whether the simultaneous use of both markers is
helpful in improving patient risk stratification.
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Methods
Study Population
From May 2006 to July 2010, ambulatory patients treated at a
multidisciplinary HF unit were consecutively included in the study.
Patients were referred to the unit by cardiology or internal
medicine departments and, to a lesser extent, from the emergency
or other hospital departments. The principal referral criteria were
HF according to the European Society of Cardiology guidelines
irrespective of etiology, and at least one HF hospitalization and/or
reduced left ventricular ejection fraction (LVEF). Blood samples
were obtained by venipuncture between 9:00 a.m. and 12:00 p.m.
during conventional ambulatory visits, and adequately centrifuged
serum samples were stored at 280uC. Both cystatin-C and
creatinine were analyzed from the same blood sample.
All participants provided written informed consent, and the
local ethics committee approved the study. All study procedures
were in accordance with the ethical standards outlined in the
Helsinki Declaration of 1975 as revised in 1983.
Follow-up and Outcomes
All patients were followed at regular predefined intervals with
additional visits as required in the case of decompensation. The
regular visitation schedule included a minimum of quarterly visits
with nurses, biannual visits with physicians, and elective visits with
geriatricians, psychiatrists, and rehabilitation physicians [11,14].
Patients who did not attend the regular visits were contacted by
telephone.
Death from all causes was the main outcome. Fatal events were
identified from the clinical records of the HF unit, other hospital
wards, the emergency room, general practitioners, and by
contacting the patient’s relatives. The data were verified using
the databases of the regional and national health systems.
Glomerular Filtration Rate
The eGFR was calculated using the Cockroft-Gault formula:
(140-age in years)6weight in kilograms/(726serum creatinine
level in mg/dl) adjusted by sex (60.85 in women) [8], and then
adjusted by body surface area [11]. Serum creatinine levels were
analyzed using the CREA method with a DimensionH Clinical
Chemistry System (Siemens, Newark, USA) and a modification of
the kinetic Jaffe reaction described by Larsen with picrate as the
reactant.
Cystatin-C
Cystatin-C was measured using a nephelometric technique that
assesses immune complex formation between cystatin and
antiserum anticystatin-C attached to latex particles. Assays were
processed twice by a Delta nephelometer (ref. 010138; Radim
SPA, Pomezia, Italy, ref NPP42). The coefficient of variation
between assays was 2.9%. Normal values are 0.53–0.95 mg/L.
Statistical Analysis
Categorical variables were expressed as percentages. Continu-
ous variables were expressed as the mean (standard deviation) or
median (25th and 75th percentiles [P25–75]) according to normal or
non-normal distribution. Differences in cystatin-C levels between
groups were compared using the Mann-Whitney and Kruskal
Wallis tests, and correlations between cystatin-C and continuous
variables were evaluated using the Rho Spearman coefficient.
Colinearity between eGFR and Cystatin-C was assessed with
Eigen-values analysis, Condition Index and Variance Inflation
Factor.
Survival analyses were performed using Cox regression models
incorporating the following variables: age, sex, New York Heart
Association (NYHA) functional class, ischemic etiology of HF,
LVEF (in %), HF duration, presence of diabetes mellitus, chronic
obstructive lung disease and peripheral artery disease, plasma
hemoglobin (g/dl), serum sodium (mmol/L), b-blocker treatment,
and angiotensin-converting enzyme inhibitor (ACEI) or angioten-
sin II receptor blocker (ARB) treatment, together with eGFR (in
ml/min/1.73 m2) or cystatin-C. A Cox regression model with
both renal markers was also performed. Kaplan-Meier survival
curves were plotted for eGFR and cystatin-C quartiles and the
groups compared using the log-rank test. In addition, Kaplan-
Meier survival curves were plotted for cystatin-C levels below or
above the median for each quartile of eGFR.
We used different measurements of performance to test the
potential incremental prognostic value of the two renal biomark-
ers.
a) Discrimination: The area under the receiver operating
characteristic curve (AUC) summarized the diagnostic
discrimination. Discrimination refers to a model’s ability to
distinguish two classes of outcomes correctly. We used the
index of rank correlation, Somers’ D, which already
incorporates information from censored data. AUCs between
models were compared using the U-statistic test for equality
concordance.
b) Calibration: The D’Agostino–Nam version of the Hosmer
and Lemeshow calibration test was used to calculate a chi-
square value. A model is well calibrated when predicted and
observed values agree for any reasonable grouping of the
observation (no significant differences in the Hosmer–
Lemeshow test). In addition, the Bayesian information
criterion (BIC), the Akaike information criterion (AIC), and
the Brier score were calculated for each model. Given any
two estimated models, the model with the lower BIC, AIC,
and Brier scores was preferred. No statistical tests compare
different BIC, AIC, or Brier estimations, and lower values
indicate a better model. When a biomarker was added to
another, the global goodness-of-fit of the model was evaluated
by a likelihood ratio test.
c) Reclassification: We used the method described by Pencina et
al [15]. Two main statistics are used to assess reclassification.
The integrated discrimination improvement (IDI) considers
changes in the estimated mortality prediction probabilities as
a continuous variable. P-values less than 0.05 from two-sided
tests were considered significant. The net reclassification
improvement (NRI) requires a previous definition of
meaningful risk categories (we used tertiles for the risk of
death: ,18.5%, 18.5–41%, and .41%). The NRI considers
changes in the estimated mortality prediction probabilities
that imply a change from one category to another.
All analyses were performed using the software R (version
2.11.1) statistical package (Foundation for Statistical Computing,
Vienna, Austria).
Results
Out of 891 consecutive patients included from May 22, 2006 to
July 7, 2010, eGFR and cystatin-C were available in 879, which
were finally included in this analysis. Median age of 70.4 years
(P25–75 60.5–77.2 years). Table 1 shows the baseline characteristics
of the entire sample. During a median follow-up period of 3.46
years (P25–75 1.85–5.05), 312 patients died. Among the cardiovas-
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cular causes of death (167), refractory HF was responsible in 90
(53.9%) patients, sudden death in 31 (18.5%) patients, and acute
myocardial infarction in 15 (9.0%) patients. Two patients were lost
to follow-up and adequately censored.
Cystatin-C Levels
Cystatin-C levels correlated significantly with age (Rho 0.44,
P,0.001) and eGFR (Rho 20.82, P,0.001), but not with LVEF
(Rho 0.05, P= 0.12). However, no consistent colinearity was found
between Cystatin-C and eGFR. Cystatin-C levels were signifi-
cantly higher in women (P= 0.005), diabetic patients (P,0.001),
hypertensive patients (P,0.001), and in patients not treated with
b-blockers or ACEI-ARB. No relationship was found between
cystatin-C levels and ischemic or non-ischemic HF etiology. In
addition, cystatin-C levels progressively increased with worse
NYHA functional class (P,0.001).
Cox Regression and Modeling
In the bivariable analysis, both eGFR and cystatin-C predicted
death from all causes as continuous variables (eGFR hazard ratio
[HR] 0.97 [95% confidence interval (CI) 0.96–0.97], P,0.001;
cystatin-C HR 1.30 [95% CI, 1.21–1.40], P,0.001). In separate
multivariable analyses, both biomarkers remained independent
predictors of mortality (Table 2). When both variables were
incorporated into the multivariable analysis, a significant interac-
tion was found (P= 0.001, Table 2), indicating that the effect of
cystatin-C on prognosis differs according to eGFR.
Kaplan–Meier survival curves according to eGFR (Figure 1A)
and cystatin-C levels (Figure 1B) and divided into quartiles showed
significant predictive prognostic values (log rank test chi-square
105.8 and 107.2; P,0.001 for both). When cystatin-C was
analyzed as an addition to eGFR, its value for risk stratification
was only present in moderate renal dysfunction patients (quartiles
2 and 3, eGFR 30–60 ml/min/1.73 m2, Figure 2).
Measurements of Performance
eGFR vs. cystatin-C. The AUC for the prediction of death
was very similar for eGFR and cystatin-C in the adjusted model
(Table 3). The P-values for the Hosmer–Lemeshow statistics
indicated good calibration for both markers (P.0.56 for all
comparisons). Also BIC, AIC, and Brier scores were very similar
for both markers (Table 3). Taking the model with eGFR as a
reference, IDI (risk as a continuous variable) and NRI (reclassi-
fication according to predefined risk categories) decreased
significantly with cystatin-C (20.5 [21.0;20.1], P= 0.024 and
24.9 [28.8;21.0], P= 0.013, respectively) (Table 3).
Combined addition of eGFR and cystatin-C. The com-
bined addition of the two markers in the adjusted model did not
improve discrimination, calibration, or reclassification according
to IDI and NRI (NRI was significantly worse:22.0 [23.9;20.21],
P= 0.034). However, when the variable interaction eGFR6cysta-
tin-C was included in the model, the global goodness-of fit
increased significantly (likelihood ratio P-value = 0.002) and
reclassification using IDI significantly improved (1.0 [0.2;1.8],
P= 0.01) with respect to the model with eGFR alone (Table 3),
suggesting that cystatin-C affects prognosis according to eGFR.
Discussion
Cystatin-C is a protein that belongs to a group of cysteine
proteinase inhibitors, one of the four types of proteinases in
mammalian cells. These types of proteins are encoded by the so-
called housekeeping genes that regulate the factors necessary for
global cell function, and all nucleated cells produce them at a
stable production rate [16]. The protein is located extracellularly
and detected mainly in biological fluids. Because of its small size,
cystatin-C is freely filtered by the glomerulus and is not secreted,
reabsorbed, or catabolized in the proximal tubules; it does not
return to the blood and is not detected in urine [17]. Production
depends on the metabolic rate and increases in hypermetabolic
situations, such as hyperthyroidism and corticosteroid treatment
[18]. Cystatin-C has been reported to provide a more accurate
and precise estimate of GFR than serum creatinine [19–22]. In
Table 1. Demographic and clinical baseline characteristics
and treatments during follow-up.
N = 879
Age, yr* 70.4 (60.5–77.2)
Males–no. (%) 631 (71.8)
White–no. (%) 874 (99.6)
Etiology–no. (%)
Ischemic heart disease 463 (52.7)
Dilated cardiomyopathy 87 (9.9)
Hypertensive 80 (9.1)
Etoh 50 (5.7)
Toxic 23 (2.6)
Valvular 100 (11.4)
Other 76 (8.6)
HF duration, months* 26.9 (4–72)
LVEF, in %* 34 (26–43)
BMI, kg/m2* 26.9 (24.2–30.5)
NYHA functional class–no. (%)
I 65 (7.4)
II 578 (65.8)
III 228 (25.9)
IV 8 (0.9)
Hypertension–no. (%) 537 (61.1)
Diabetes mellitus–no. (%) 314 (35.7)
COLD–no. (%) 146 (16.6)
Treatments–no. (%)
ACEI or ARB 791 (90.0)
b-blocker 771 (87.7)
Spironolactone/eplerenone 345 (39.2)
Loop diuretic 742 (84.4)
Digoxin 267 (30.4)
ICD 93 (10.6)
CRT 47 (5.3)
Sodium, mmol/L* 139 (137–142)
Hemoglobin, g/dl{ 13.061.8
eGFR, ml/min/1.73 m2* 42.4 (29.4–59.4)
Cystatin-C, mg/L* 1.21 (0.96–1.61)
*median (percentiles 25th and 75th).
{(mean 6 standard deviation).
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor
blocker; BMI, body mass index; COLD, chronic obstructive lung disease; CRT,
cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate;
Etoh, alcoholic cardiomyopathy; HF, heart failure; ICD, implantable cardiac
defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Association.
doi:10.1371/journal.pone.0051234.t001
Cys-C and EGFR for HF Risk Stratification
PLOS ONE | www.plosone.org 3 December 2012 | Volume 7 | Issue 12 | e51234
this study of a HF population, we found that cystatin-C levels were
influenced by age, sex, NYHA functional class, eGFR, treatments,
and comorbidities, such as diabetes and hypertension.
In recent years, cystatin-C has emerged as a marker of
cardiovascular events and mortality in different situations. For
example, in patients with ischemic heart disease, cystatin-C was
found to be an independent risk factor together with traditional
cardiovascular risk factors, renal function, or the presence of
microalbuminuria [23]. The combined association of albuminuria
and cystatin-C-based eGFR was associated with mortality,
coronary heart disease, and HF outcomes in the ARIC community
study [24]; and in the Cardiovascular Health Study it was a more
powerful predictor of death and cardiovascular events in the
elderly than creatinine [25]. Remarkably, the usefulness of
cystatin-C as a cardiovascular-related prognostic biomarker has
been linked not only to its ability to estimate renal function, but
also to its relationship with ventricular remodeling and fibrosis and
vascular wall stiffness [26–27].
In the specific setting of HF, most of the information on the
prognostic usefulness of cystatin-C derive from acutely decom-
pensated HF patients, and the data are encouraging. Lassus et al.
[12] found that cystatin-C was a strong predictor of mortality in
480 patients hospitalized for acute HF, both in-hospital and during
1 year of follow-up, and was independent of other renal markers
(serum creatinine and eGFR values estimated using the Cockroft-
Gault formula). Interestingly, Naruse et al.[28] found the best
relationship between high levels of cystatin-C and the risk of
cardiac death in patients with acute HF and an eGFR calculated
by the MDRD formula between 44 and 79 ml/min/1.73 m2,
independent of volemia and body weight. Cystatin-C was also an
independent predictor of prognosis at 2 years of follow-up for the
occurrence of death, heart transplantation, or readmission due to
worsening HF in 138 systolic HF patients admitted for acute
descompensation [29].
In contrast, little information exists on the value of cystatin-C in
chronic HF. The first work that examined the ability of cystatin-C
to predict mortality in these patients was published by Shlipack et
al. [13], who analyzed a subgroup of 279 patients with prevalent
HF from the Cardiovascular Health Study. Cystatin-C was
exclusively assessed by Cox regression analysis and remained a
better independent pronosticator than creatinine and eGFR
calculated by the simplified MDRD equation. Arimoto et al.
[30], analyzing 140 patients with HF and 64 control subjects,
found that serum cystatin-C levels were higher in the patients with
HF. Patients with high cystatin-C levels had a markedly higher
cardiac event rate (cardiac death and HF hospitalization),
independent of creatinine levels. A recent publication [31] in a
small cohort of 102 young patients with chronic HF assessed
creatinine, eGFR calculated by MDRD and simplified MDRD
formulas, and cystatin-C as predictors of renal function using
isotope glomerular filtration rate as the gold standard. Despite the
small number of recorded events (8 deaths, 10 HF hospitalizations,
and 3 heart transplantations), cystatin-C levels were similar to both
eGFR formulas for predicting renal function and had similar
prognostic properties as MDRD and simplified MDRD in ROC
analysis and Cox regression analysis. Our study included a
substantially larger cohort of patients (879 vs. 102) who were older
(median 70 years vs. mean 58 years), had greater impairment of
renal function (eGFR 42.4 ml/min/1.73 m2 vs. 65 ml/min/
1.73 m2), and higher cystatin-C levels (1.21 vs 0.8 mg/L). The
follow-up also differed significantly (3.5 years vs. 2 years) and the
number of deaths was much higher (312 vs. 8). The additional
prognostic information gained by any marker over a clinical risk
model plus other biomarkers needs to be determined using
adequate statistical tools [32]; therefore we performed a very
Table 2. Multivariable Cox Regression analyses.
Model with eGFR Model with Cystatin-C
Model with eGFR, Cystatin-C and
interaction eGFR6Cystatin-C
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Age 1.05 [1.03;1.06] ,0.001 1.06 [1.04;1.07] ,0.001 1.05 [1.03;1.07] ,0.001
Female gender 0.75 [0.57;0.98] 0.036 0.74 [0.56;0.97] 0.031 0.75 [0.57;0.98] 0.037
NYHA functional class 1.74 [1.36;2.22] ,0.001 1.71 [1.33;2.18] ,0.001 1.65 [1.29;2.11] ,0.001
Diabetes mellitus 1.25 [0.99;1.57] 0.064 1.25 [0.99;1.58] 0.061 1.25 [0.99;1.58] 0.06
Beta-blocker treatment 0.5 [0.37;0.67] ,0.001 0.51 [0.38;0.7] ,0.001 0.49 [0.36;0.67] ,0.001
ACEI or ARB treatment 0.58 [0.42;0.79] ,0.001 0.59 [0.43;0.81] 0.001 0.58 [0.43;0.8] ,0.001
LVEF 0.99 [0.98;1] 0.057 0.99 [0.98;1] 0.032 0.99 [0.98;1] 0.05
Ischemic aetiology of HF 1.02 [0.8;1.3] 0.877 1.02 [0.8;1.3] 0.874 1.04 [0.81;1.33] 0.743
HF duration 1 [1;1] 0.044 1 [1;1] 0.043 1 [1;1] 0.062
COLD 1.14 [0.86;1.51] 0.349 1.16 [0.88;1.53] 0.303 1.1 [0.83;1.45] 0.524
Peripheral artery disease 1.52 [1.13;2.03] 0.005 1.51 [1.13;2.02] 0.006 1.48 [1.1;1.98] 0.009
Na, mmol/L 0.95 [0.92;0.98] ,0.001 0.95 [0.92;0.98] 0.001 0.95 [0.92;0.98] ,0.001
Hb, g/dL 0.88 [0.82;0.95] ,0.001 0.87 [0.81;0.93] ,0.001 0.9 [0.84;0.97] 0.005
eGFR, ml/min/1.73m2 0.99 [0.98;1] 0.006 - - - 0.97 [0.96;0.99] ,0.001
Cystatin-C - - - 1.14 [1.02;1.28] 0.02 0.89 [0.72;1.09] 0.249
Interaction eGFR6Cystatin-C - - - - - - 1.02 [1.01;1.03] ,0.001
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; COLD, chronic obstructive lung disease; eGFR, estimated
glomerular filtration rate; Hb, plasma hemoglobin; HF, heart failure; LVEF, left ventricular ejection fraction; Na, serum sodium; NYHA, New York Heart Association (I–II vs.
III–IV).
doi:10.1371/journal.pone.0051234.t002
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comprehensive state-of-the-art statistical analysis that included
multivariate Cox regression, discrimination, calibration, and
reclassification indices. In our study, cystatin-C had a similar
predictive long-term prognostic value as eGFR estimated by the
Cockroft-Gault formula after adjusting for some covariates
according to discrimination, calibration, and Cox regression,
though reclassication was poorer according to IDI and NRI.
Importantly, and not assessed in previous studies, we found that
when both markers were used together, cystatin-C levels
significantly affected prognosis, and differently according to eGFR.
Remarkably, we found that cystatin-C improved risk stratification,
mainly in patients with an eGFR between 30 and 60 ml/min/
1.73 m2. This finding is in agreement with a previous study [28] in
Figure 1. Kaplan–Meier survival curves according to eGFR and cystatin-C levels. Caption: Both eGFR levels (Panel A) and cystatin-C levels
(Panel B) have been divided in quartiles.
doi:10.1371/journal.pone.0051234.g001
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Figure 2. Kaplan–Meier survival curves according to cystatin-C levels in patients with an eGFR between 30 and 60 ml/min/1.73 m2.
Caption: cystatin-C levels have been divided according to median values (below vs. equal/above). N = 443.
doi:10.1371/journal.pone.0051234.g002
Table 3. Performance of the adjusted models at 4 years.
Model with eGFR Model with Cystatin-C
Model with both eGFR and
Cystatin-C
Model with eGFR, Cystatin-C and interaction
eGFR6Cystatin-C
AUC 0.763 (0.737;0.79) 0.765 (0.739;0.791) 0.764 (0.738;0.79) 0.768 (0.742;0.794)
reference p-value: 0.577 p-value: 0.254 p-value: 0.159
H-L Chi-square: 6.1 Chi-square: 7.7 Chi-square: 7.3 Chi-square: 4.4
p.value = 0.73 p.value = 0.568 p.value = 0.608 p.value = 0.881
Brier score 0.16 0.16 0.159 0.157
AIC 3656.5 3659.4 3658.2 3648.5
BIC 3723.2 3726.1 3729.7 3724.8
Likelihood R – – *p.value = 0.584 *p.value = 0.002
IDI 20.5 [21.0;20.1], 20.03 [20.1;0.1], 1.0 [0.2;1.8],
reference *p-value = 0.024 *p-value = 0.619 *p-value = 0.01
NRI-All 24.9 [28.8;21.0], 22.0 [23.9;20.2], 2.4 [22.6;7.5],
reference *p-value = 0.013 *p-value = 0.034 *p-value = 0.343
NRI-Cases 23.1 [25.9;20.2], 21.4 [22.8;,0.1], 2.0 [21.8;5.9],
reference *p-value = 0.033 *p-value = 0.045 *p-value = 0.298
NRI-Control 21.8 [24.2;0.6], 20.6 [21.8;0.6], 0.4 [22.4;3.2],
reference *p-value = 0.133 *p-value = 0.336 *p-value = 0.783
*Versus model 1.
AUC, area under the ROC curve; AIC, Akaike information criterion; BIC, Bayesian information criterion; H-L, Hosmer and Lemeshow test; Likelihood R: Goodness-of-fit
assessed by likelihood ratio; IDI, integrated discrimination improvement; NRI, net reclassification improvement.
Covariates included in models: Age, Female gender, NYHA functional class, Diabetes mellitus, Beta-blocker treatment, ACEI or ARB treatment, LVEF, Ischemic aetiology
of HF, HF duration, COLD, Peripheral artery disease, Na, Hb.
doi:10.1371/journal.pone.0051234.t003
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acutely decompensated HF patients (eGFR between 44 and
79 ml/min/1.73 m2).
Doubts still exist about the exact mechanism by which cystatin-
C has predictive value in HF and whether its prognostic capacity
goes beyond renal function. Damman et al. [31] studied the
relationship between cystatin-C and inflammation; though they
could not exclude some relationship between cystatin-C levels and
several inflammatory markers, this effect seemed small in relation
to the strong association between cystatin-C and glomerular
filtration rate. Furthermore, whether the relationship of cystatin-C
with the mechanisms of ventricular remodeling may influence its
predictive role is unknown. Taking into account the reduced
availability of cystatin-C in routine laboratories and the cost, its
usefulness as a prognostic factor should only be considered in
patients with moderate degrees of renal dysfunction and it is
advisable to continue using the classical eGFR formulas.
This study has some limitations. The optimal time for
determining cystatin-C in regards to the clinical situation and if
it is better to make serial or a single determination are unknown.
We have no data about the presence of hyperthyroidism,
inflammatory parameters, or the use of corticosteroids, which
may be related to metabolism and protease levels. Our population
was a general HF population treated at a specific and multidis-
ciplinary HF unit in a tertiary hospital; most patients were referred
from the cardiology department and, accordingly, mainly expe-
rienced HF of ischemic etiology with reduced LVEF. As such,
these results cannot necessarily be extrapolated to a global HF
population.
Conclusions
The eGFR and cystatin-C have a similar long-term prognostic
value in ambulatory HF patients when analyzed in a model
adjusted by several established mortality risk factors. Cystatin-C
seems to offer improved prognostication in heart failure patients
with moderate renal dysfunction.
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